| Product/ Candidate |
Therapeutic Area |
Stage
Discovery
POC
FDA |
Academic |
Commercial |
|---|---|---|---|---|
 |
Substance Use Disorder |
 |
||
 |
Opioid Use Disorder |
|
||
| Somryst™ * | Insomnia/ Depression |
 |
||
| PEAR-004 * | Schizophrenia (Pos Sx) |
 |
||
| DISCOVERY * | Cognition |
|
||
| DISCOVERY * | Epilepsy | |||
| reCALL™ * | PTSD |  |
||
| PEAR-007 * | Pain | |||
| DISCOVERY * | Movement Disorders | |||
| PEAR-006 * | Multiple Sclerosis | |
||
| DISCOVERY * | Migraine | |||
| DISCOVERY * | Autism Spectrum Disorder |
|
||
| DISCOVERY * | Oncology, Inflammation, CV, GI, Respiratory | |||
* FDA has not determined the safety or effectiveness of this product candidate.
